{
    "organizations": [],
    "uuid": "bb29fad50e8e8386df652dc7f8f3a2917191f62e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ovid-therapeutics-reports-q4-loss/brief-ovid-therapeutics-reports-q4-loss-per-share-0-45-idUSASC09UA9",
    "ord_in_thread": 0,
    "title": "Ovid Therapeutics Reports Q4 Loss Per Share $0.45",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29 (Reuters) - Ovid Therapeutics Inc:\n* OVID THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE PROGRESS\n* Q4 LOSS PER SHARE $0.45 * Q4 EARNINGS PER SHARE VIEW $-0.41 â€” THOMSON REUTERS I/B/E/S\n* OVID THERAPEUTICS - PLAN TO INITIATE PHASE 2 CLINICAL TRIAL WITH OV101 FOR TREATMENT OF ADOLESCENTS AND YOUNG ADULTS WITH FRAGILE X SYNDROME IN 2018\n* TOPLINE DATA FOR PHASE 1B/2A CLINICAL TRIAL OF TAK-935/OV935 EXPECTED IN SECOND HALF 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-30T04:29:00.000+03:00",
    "crawled": "2018-03-30T12:48:10.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "ovid",
        "therapeutic",
        "inc",
        "ovid",
        "therapeutic",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "corporate",
        "progress",
        "q4",
        "loss",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "ovid",
        "therapeutic",
        "plan",
        "initiate",
        "phase",
        "clinical",
        "trial",
        "ov101",
        "treatment",
        "adolescent",
        "young",
        "adult",
        "fragile",
        "x",
        "syndrome",
        "topline",
        "data",
        "phase",
        "clinical",
        "trial",
        "expected",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}